Immune Checkpoint Inhibitors market is estimated to grow at a CAGR of 13.3% during the forecast period of 2023-2030: Cognitive Market Research

Market Overview:
• A type of drug known as an immune checkpoint inhibitor prevents immune system cells including T cells and cancer cells from producing checkpoint proteins. In some circumstances, these checkpoints prevent T cells from destroying cancer cells and inhibit too-aggressive immune responses. When these checkpoints are shut down, T lymphocytes are more effective in its attack on cancer cells. Two checkpoint proteins were found on T cells or cancer cells: PD-1/PD-L1 and CTLA-4/B7-1/B7-2. Immune checkpoint inhibitors are used to treat cancer.

Summary:
• The Global Immune Checkpoint Inhibitors market is estimated to be valued at USD 1,445.7 million in 2022 and is expected to exhibit a CAGR of 13.3% during the forecast period (2023-2030).

"To know more about The Immune Checkpoint Inhibitors Market statistics click here: https://www.cognitivemarketresearch.com/immune-checkpoint-inhibitors-market-report

What is the driving factor for the global Immune Checkpoint Inhibitors Market?
- Growth & innovations in the pharmaceutical industry for cancer treatment due to enhanced therapeutic result drives the demand for the global immune checkpoint inhibitors market. In addition, an increase in the number of cancer and chronic disorders and the adoption of a sedentary lifestyle is forecasted to dominate the global market.
Immune Checkpoint Inhibitors Market Opportunity
- A rise in the number of R&D activities by various major players across the globe and increasing approval of the immune checkpoint inhibitors by regulatory bodies are expected to drive the global immune checkpoint market.
What is the restraining factor for the global Immune Checkpoint Inhibitors Market?
- The high price of immuno-oncology treatments, which is unaffordable to low and middle-income populations drives the demand for the global market.

Market Segmentation:
Drug Class:
• Programmed Death Receptor-1 (PD-1) Inhibitors
• Programmed Death-Ligand 1 (PD-L1) Inhibitors
• CTLA-4 Checkpoint Inhibitor
• Indoleamine-2,3-dioxygenase (IDO) Inhibitors
• Lymphocyte-Activation Gene 3 Inhibitors
The programmed Death Receptor-1 (PD-1) Inhibitors segment is forecasted to dominate the global market, due to the rising adoption of PD-1 inhibitors such as pembrolizumab and nivolumab across the globe.

Cancer Type:
• Blood Cancer (Lymphoma)
• Bladder Cancer (Urothelial Carcinoma)
• Lung Cancer
• Renal/Kidney Cancer
• Colorectal Cancer
• Head & Neck Cancer
• Skin Cancer (Melanoma and Merkel Cell Carcinoma)
• Breast Cancer
• Others
The lung cancer segment dominates the global market with the highest revenue share. This is attributed to the growth in the use of immune checkpoint inhibitors for the treatment of lung cancer increase in the incidences of lung cancer across the globe drives the demand for the target market.

Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The Major Players Immune Checkpoint Inhibitors Market are:
Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation, NewLink Genetics, ArGEN X, Seattle Genetics, Pfizer, MacroGenics, Celldex Therapeutics, CureTech, Immutep, Innate Pharma, Sorrento Therapeutics, GlaxoSmithKline, GITR Inc

Get free sample pages of the latest published Immune Checkpoint Inhibitors Report:
https://www.cognitivemarketresearch.com/immune-checkpoint-inhibitors-market-report/report_enquiry?id=4

Market's Recent Development
Bristol Myers Squibb received the approval for opdivo (nivolumab)
April 2022: Bristol Myers Squibb received the European Commission approval for opdivo (nivolumab) with chemotherapy as first-line treatment for patients with unresectable advanced, recurring, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression of 1% or higher.

Browse here for Full TOC:
Table of Content (Revenue USD Edition), (Enquire about Volume/Consumption Edition Data)
Chapter 1 Industrial Insight and Market Scope
• 1.1 Global Immune Checkpoint Inhibitors Industry Introduction
• 1.2 Objectives of the Study
• 1.3 USP of the Report
• 1.4 Who is this report for?
• 1.5 Designing of Market Scope
1.5.1 Immune Checkpoint Inhibitors Market Segmentation
1.5.1 Immune Checkpoint Inhibitors Market Regional Fragmentation
1.5.1 Immune Checkpoint Inhibitors Market Players
• 1.6 Report Duration
• 1.7 List of Stakeholders
Chapter 2 Research MethodologyReview Complete Research Methodology
Chapter 3 Executive Summary of Immune Checkpoint Inhibitors Market
Chapter 4 Global Immune Checkpoint Inhibitors Market Overview
Chapter 5 Competitive Analysis (Subject to Availability)
Chapter 6 Environmental, Social, and Governance (ESG) Analysis
Chapter 7 Qualitative Analysis
Chapter 8 Company Profiling (Subject to Availability)
Chapter 9 Global Immune Checkpoint Inhibitors Market by Type Segmentation Analysis (2018-2030)
Chapter 10 Global Immune Checkpoint Inhibitors Market by Cancer Type Segmentation Analysis (2018-2030)
Chapter 11 Global Immune Checkpoint Inhibitors Market by Distribution Channel Segmentation Analysis (2018-2030)
Chapter 12 Global Immune Checkpoint Inhibitors Market Regional Analysis
Chapter 13 North America Immune Checkpoint Inhibitors Market Outlook (2018 - 2030)
Chapter 14 Europe Immune Checkpoint Inhibitors Market Outlook (2018 - 2030)
Chapter 15 Asia Pacific Immune Checkpoint Inhibitors Market Outlook (2018 - 2030)
Chapter 16 Latin America Immune Checkpoint Inhibitors Market Outlook (2018 - 2030)
Chapter 17 Middle East and Africa Immune Checkpoint Inhibitors Market Outlook (2018 - 2030)
Chapter 18 Research Findings
Customize the Report Edition (Is applicable, On Request, Subject to Data Available, At an Additional Cost)

To know more about Immune Checkpoint Inhibitors Market TOC click here: https://www.cognitivemarketresearch.com/immune-checkpoint-inhibitors-market-report#table_of_contents

Related Report
• Interleukin Inhibitors Market - https://www.cognitivemarketresearch.com/interleukin-inhibitors-market-report
• Immune Checkpoint blockers Market - https://www.cognitivemarketresearch.com/immune-checkpoint-blockers-market-report
• Tyrosine Kinase Inhibitors Market - https://www.cognitivemarketresearch.com/tyrosine-kinase-inhibitors-market-report

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬
Nicolas Shaw
Cognitive Market Research
20 N State Street,Chicago,
Illinois, 60602
United States
USA: +1 312-376-8303
Europe and UK: (+44) 20-8144-9523
Asia Pacific: (+852) 81930785
Email: sales@cognitivemarketresearch.com
Website: https://www.cognitivemarketresearch.com/about-us

About Cognitive Market Research Company :
Cognitive Market Research has evolved as one leading market research and consulting firm and it provides services across multiple domains. Cognitive Market Research gathers and analyzes data about customers, competitors, distributors, and other market actors and forces operating across the value chain. As a market research company, we follow a complete process of gathering information about the target market and end-use industries to verify the complete journey of the product or service in the global market. It helps our readers understand the demand and viability of their product/service and how it might perform in the real world and help them to build business strategies accordingly.

This release was published on openPR.